Independent Director Bruce Perkins Just Bought 3.7% More Shares In Amedisys, Inc. (NASDAQ:AMED)
Investors who take an interest in Amedisys, Inc. (NASDAQ:AMED) should definitely note that the Independent Director, Bruce Perkins, recently paid US$259 per share to buy US$259k worth of the stock. While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just 3.7%.
View our latest analysis for Amedisys
The Last 12 Months Of Insider Transactions At Amedisys
In fact, the recent purchase by Independent Director Bruce Perkins was not their only acquisition of Amedisys shares this year. They previously made an even bigger purchase of US$335k worth of shares at a price of US$167 per share. We do like to see buying, but this purchase was made at well below the current price of US$241. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
In the last twelve months insiders purchased 6.00k shares for US$1.0m. On the other hand they divested 226.00 shares, for US$50k. Overall, Amedisys insiders were net buyers during the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
Amedisys is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership of Amedisys
Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Amedisys insiders own 2.1% of the company, currently worth about US$161m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
What Might The Insider Transactions At Amedisys Tell Us?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Amedisys. That's what I like to see! So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 1 warning sign with Amedisys and understanding this should be part of your investment process.
But note: Amedisys may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
